COGT Share Price | Cogent Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Cogent Biosciences, Inc. do?

Overview:Cogent Biosciences, Inc. is a biopharmaceutical company focused on developing precision therapies for genetically defined diseases and curative cell therapies for solid tumors, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: Not availableMost recent Net Profit: -72 Million (Quarterly Results - Mar 2025)Market-cap: USD 867.59 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.11Return on Equity: -123.06%Price to Book: 3.96Contact Details:Address: 200 CAMBRIDGE PARK DRIVE, SUITE 3100, CAMBRIDGE MA: 02140Tel: ['1 617 9455576', '1 212 3621200']Website: https://www.unumrx.com/

Q: Is Cogent Biosciences, Inc. overvalued or undervalued?

As of 12 May 2021, the valuation grade for Cogent Biosciences, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial ratios, including a Price to Book Value of 3.54, an EV to EBIT of -1.84, and an ROE of -123.06%. These figures suggest that the company is not generating returns on equity and is facing substantial operational challenges.In comparison to its peers, Cogent's valuation metrics are considerably worse. For instance, Protagonist Therapeutics, Inc. has a P/E ratio of 60.90, while Deciphera Pharmaceuticals, Inc. shows a P/E of -11.62, both indicating a stark contrast to Cogent's situation. The company's recent stock performance has also been lackluster, with a one-year return of -17.41% compared to the S&P 500's 10.26%, further reinforcing the notion that Cogent is overvalued in its current state.

Q: Is Cogent Biosciences, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Cogent Biosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the RSI shows a bearish signal. The daily moving averages are bullish, and the KST is bullish on both weekly and monthly time frames. However, Dow Theory presents a mildly bearish view on the weekly chart, contrasting with a mildly bullish monthly perspective. In terms of performance, the stock has returned 60.38% year-to-date, significantly outperforming the S&P 500's 13.31% during the same period, although it has underperformed over the longer 3-year and 5-year horizons. Overall, the current technical stance is mildly bullish, driven by strong indicators like MACD and Bollinger Bands, despite some mixed signals from the RSI and Dow Theory.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.4 M

Shareholding (Dec 2025)

FII

8.22%

Held by 111 FIIs

DII

36.49%

Held by 55 DIIs

Promoter

19.10%

How big is Cogent Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Cogent Biosciences, Inc. has a market capitalization of 867.59 million and reported net sales of 0.00 million with a net profit of -269.50 million over the last four quarters. Shareholder's funds were 256.29 million, and total assets amounted to 327.90 million as of Dec 24.

View full answer

What does Cogent Biosciences, Inc. do?

22-Jun-2025

Cogent Biosciences, Inc. is a biopharmaceutical company focused on developing precision therapies for genetically defined diseases and curative cell therapies for solid tumors. It operates as a micro-cap company with a market cap of approximately $867.59 million and reported a net profit loss of $72 million in March 2025.

View full answer

Who are in the management team of Cogent Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Cogent Biosciences, Inc. includes Andrew Robbins (President and CEO), Chris Cain, Peter Harwin, Karen Ferrante, Arlene Morris, and Matthew Ros, all of whom guide the company's strategic direction and operations.

View full answer

Is Cogent Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of May 12, 2021, Cogent Biosciences, Inc. is considered overvalued due to negative financial ratios and poor stock performance, indicating significant operational challenges compared to its peers.

View full answer

Is Cogent Biosciences, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Cogent Biosciences, Inc. shows a mildly bullish trend with strong indicators like MACD and Bollinger Bands, despite mixed signals from the RSI and Dow Theory, and has returned 60.38% year-to-date, outperforming the S&P 500.

View full answer

Compare Cogent Biosciences, Inc. with Similar Stocks

Prime Medicine, Inc.Immatics NV Rayzebio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5,791 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-50.56%

Price to Book

9.10

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-102 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.93%

6 Months

162.42%

1 Year

360.41%

2 Years

395.25%

3 Years

191.27%

4 Years

389.44%

5 Years

310.07%

Cogent Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-252.19%

EBIT to Interest (avg)

-161.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.11

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

9.10

EV to EBIT

-15.34

EV to EBITDA

-15.56

EV to Capital Employed

-128.03

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-50.56%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 55 Schemes (36.2%)

Foreign Institutions

Held by 111 Foreign Institutions (8.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -50.96% vs -24.82% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-98.30",
          "val2": "-72.60",
          "chgp": "-35.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-102.50",
          "val2": "-67.90",
          "chgp": "-50.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -28.53% vs -33.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-328.70",
          "val2": "-271.50",
          "chgp": "-21.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-328.90",
          "val2": "-255.90",
          "chgp": "-28.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-98.30

-72.60

-35.40%

Interest

1.30

0.00

Exceptional Items

-7.20

0.00

Consolidate Net Profit

-102.50

-67.90

-50.96%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -50.96% vs -24.82% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-328.70

-271.50

-21.07%

Interest

3.10

0.00

Exceptional Items

-7.20

0.00

Consolidate Net Profit

-328.90

-255.90

-28.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -28.53% vs -33.00% in Dec 2024

All Annual Results

Company CV

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

Pharmaceuticals & Biotechnology

Cogent Biosciences, Inc., formerly Unum Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing precision therapies for genetically defined diseases. The Company also engaged in developing curative cell therapies for solid tumors. Its proprietary technology includes bolt-on chimeric receptor (BOXR), designed to overcome resistance of the solid tumor microenvironment (TME) to T cell attack. The Company also developed product candidates using its proprietary technology, antibody-coupled T cell receptor (ACTR), an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability. Its preclinical program offers, BOXR1030, for the treatment of solid tumor cancers and PLX9486, is a tyrosine kinase inhibitor that is designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 to treat systemic mastocytosis and gastrointestinal stromal tumors (GIST) patients.

Company Coordinates

Company Details

200 CAMBRIDGE PARK DRIVE, SUITE 3100 , CAMBRIDGE MA : 02140

Tel: 1 617 94555761 212 3621200

https://www.unumrx.com/

Registrar Details